 In this study, the investigators will administer Fluzone High-Dose vaccine with a planned booster to patients with monoclonal gammopathies irrespective of age versus a standard of care control group. Primary endpoint is composite of documented influenza infection rate and disease progression as defined by International Myeloma Working Group criteria at the end of the flu season. Based on the background data, the investigators expect a higher rate of success in the experimental arm. As such, the investigators power for success rates of 90 and 70 in the experimental and control arms, respectively. 